Jill Cottel, MD - Treating the Zebras in Primary Care (2017 Conference) (LDN, low dose naltrexone)

In this presentation Dr Cottel shares case studies of patients:

36 year old woman with Ehlers-Danlos Syndrome. This lady was started on Low Dose Naltrexone (LDN) at 1.5mg, increased to 3 mg and found she lost her earlier improvement but on going down to a much lower dose she improved significantly. 

Leonard Weinstock, MD - Celiac Disease (2017 Conference) (LDN, low dose naltrexone)

Celiac disease is a remarkable condition. It can present in so many different ways and have so many symptoms. What we're going to try is to hone down on the autoimmune conditions that are associated with it, which don't get as much attention in the literature as they should.

Leonard Weinstock, MD - POTS and Mast Cell Activation Syndromes (2017 Conference) (LDN, low dose naltrexone)

Dr Leonard Weinstock is from St Louis in Missouri and helps patients with GI Issues and other autoimmune conditions.

Pradeep Chopra, MD - Chronic Pain, Opioids and LDN (2016 Conference) (LDN, low dose naltrexone)

Download Dr. Chopra's Chronic Pain Presentation

Lauren - 1st May 2019 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Lauren is from the UK, and uses low dose naltrexone (LDN) for chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), fibromyalgia, and Ehlers-Danlos syndromes (EDS).

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.